Vicadrostat

Vicadrostat (BI 690517) is Boehringer Ingelheim's oral aldosterone synthase inhibitor, running a Phase 3 program of unusual scale in combination with empagliflozin across chronic kidney disease, heart failure with reduced ejection fraction, and now type 2 diabetes with cardiovascular disease [1][2][3][4]. The bet is that pairing an SGLT2 inhibitor Boehringer already dominates with a next-generation aldosterone blocker will deliver additive cardio-renal protection without the potassium and hormonal side effects that made older mineralocorticoid antagonists hard to tolerate. If it works, this becomes the second act for Jardiance, the company's ~$8B franchise, and a defense against generic erosion later this decade. Total Phase 3 enrollment across the four registrational trials is roughly 33,000 patients.

Vicadrostat is a novel investigational compound, never approved anywhere. It sits in a Phase 3 program running four registrational trials in parallel: EASi-KIDNEY in CKD (n=11,000, NCT06531824), two heart failure trials covering HFrEF (NCT06935370, n=4,200) and a broader HF population (NCT06424288, n=6,000), and the new EASi-PROTKT in T2D plus cardiovascular disease (NCT07064473, n=11,800), for a program total of ~33,000 patients [1][2][3][4]. A Phase 2 dose-ranging study in CKD (NCT06926660, n=492) completed and reported meaningful eGFR and albuminuria signals that greenlit the Phase 3 push [6]. No FDA breakthrough or fast-track designations have been publicly disclosed. Given trial durations of 3+ years and enrollment still active, primary readouts are unlikely before 2028-2029. Boehringer is running this on its own dime as a private company, so there are no PDUFA milestones or biotech-style catalyst dates driving the timeline. An interim look on EASi-KIDNEY around 2027 is plausible based on typical event-driven trial architecture, but Boehringer has not publicly disclosed a firm interim analysis date.

Aldosterone is a hormone made in the adrenal glands that tells your kidneys to hold onto salt and water. Too much of it drives up blood pressure, stiffens the heart, and scars the kidneys. Vicadrostat blocks CYP11B2, the enzyme that makes aldosterone, cutting off supply at the source [7]. This is different from spironolactone and eplerenone, the older mineralocorticoid receptor antagonists that block aldosterone's receptor downstream. Those drugs work but cause gynecomastia, hyperkalemia (dangerous potassium rise), and are widely underused because clinicians fear the side effects. The trick with a synthase inhibitor is selectivity: CYP11B2 is 93% identical to CYP11B1, the enzyme that makes cortisol. Hit both and you cause adrenal insufficiency. CYP11B1 cross-reactivity made first-generation compounds like osilodrostat unsuitable for hypertension, since suppressing cortisol carries stress-response risks. In an inversion, that same property turned osilodrostat therapeutic in Cushing's syndrome, where it is now FDA-approved (Isturisa, Recordati, 2020) for lowering pathologically elevated cortisol. Vicadrostat is engineered for better CYP11B2 selectivity to avoid the cortisol-suppression problem in cardio-renal indications, and has demonstrated adequate selectivity in Phase 1 and Phase 2 pharmacodynamic studies, with dose-dependent aldosterone suppression and preserved cortisol response [8][6]. Mechanistic biomarker work has also documented distinct changes in circulating urinary extracellular vesicle miRNAs on the combination [5]. The genetic validation for CYP11B2 blockade is strong: CYP11B2 gain-of-function drives familial hyperaldosteronism, loss-of-function causes low aldosterone syndromes, and mineralocorticoid antagonists have decades of outcome trial data in HFrEF (RALES, EMPHASIS-HF) and now CKD (FIDELIO with finerenone). Empagliflozin, the backbone in every Phase 3 arm, is an SGLT2 inhibitor. SGLT2 is a protein in the kidney's proximal tubule that reabsorbs filtered glucose back into blood. Blocking it dumps glucose and sodium into urine, which reduces intraglomerular pressure inside the kidney's filtering units and offloads the heart. Those hemodynamic effects, more than the glucose-lowering itself, are why SGLT2 inhibitors slow CKD progression and cut heart-failure hospitalizations. Pairing empagliflozin with an aldosterone synthase inhibitor hits two mechanistically distinct drivers of cardio-renal damage: hemodynamic load on the nephron and mineralocorticoid-driven fibrosis and sodium retention. eGFR (estimated glomerular filtration rate) is the standard measure of kidney filtration capacity, and UACR (urine albumin-to-creatinine ratio) is a marker of glomerular leakage, both used as primary or secondary endpoints in essentially every CKD outcomes trial.

The Phase 3 program is anchored on the empagliflozin combination, not vicadrostat monotherapy, which is the strategically important call. EASi-KIDNEY (NCT06531824) enrolls 11,000 CKD patients on background SGLT2i, with a composite primary endpoint of kidney disease progression, hospitalization for heart failure, or cardiovascular death [3]. EMPACT-HF-REDUCED (NCT06935370, n=4,200) tests the combo in HFrEF against empagliflozin alone, with time to CV death or HF hospitalization as primary [2]. EASi-PROTKT (NCT07064473, n=11,800) targets T2D patients with hypertension and established CVD, again composite CV death or HF event [4]. The designs are conventional Boehringer/Oxford Population Health outcome trials, well-powered, event-driven, with active comparators (empagliflozin alone) rather than placebo. The main design concern is that using empagliflozin as the comparator sets a high bar, since SGLT2 inhibitors already deliver 20-30% relative risk reductions on these endpoints. Vicadrostat has to add incremental benefit on top of an already effective backbone. Enrollment is active across all Phase 3 trials with no reported delays.

Our model estimates a 55% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase, strong earlier-phase results, and more secondary endpoints than usual; it is held back by heavier-than-usual blinding. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the primary concern. Adding vicadrostat on top of empagliflozin has to beat empagliflozin alone by a clinically and statistically meaningful margin on hard outcomes. If the incremental effect is 10-15% relative risk reduction, the trials may be underpowered despite their size. Safety risk is hyperkalemia, the class-defining toxicity of anything that blocks aldosterone. Finerenone's label carries a hyperkalemia warning and requires potassium monitoring, and vicadrostat will almost certainly be the same. The 11B1/11B2 selectivity question also remains an ongoing surveillance item: any signal of blunted cortisol response under stress would be a serious problem. Execution risk is low; Boehringer runs large cardiovascular outcome trials competently and has Oxford Population Health co-running EASi-KIDNEY, the group that ran EMPA-KIDNEY. Competitive risk from other aldosterone synthase inhibitors is now material and specific. Baxdrostat (AstraZeneca, acquired via CinCor) has an NDA under FDA Priority Review for treatment-resistant hypertension with a PDUFA date in Q2 2026, and a Phase 3 CKD-progression outcomes trial in combination with dapagliflozin (NCT06742723, and NCT06268873) with primary completion in early 2028 [13][14]. If baxdrostat lands its hypertension approval on schedule and reads out its CKD outcomes trial around the same time as EASi-KIDNEY, vicadrostat loses its first-mover positioning in the ASI class. Lorundrostat (Mineralys) is further behind but has reported Phase 2 hypertension data (~8 mmHg placebo-adjusted systolic reduction) and is advancing toward Phase 3 [15]. Commercial risk is the most underappreciated dimension. Finerenone (Kerendia, Bayer) is already approved for CKD in T2D and generated $464M in 2024 with fast growth [10]. If vicadrostat launches in 2029-2030, it walks into a market with finerenone, generic spironolactone, generic eplerenone, potentially approved baxdrostat, and generic SGLT2 inhibitors after empagliflozin's US patent situation resolves. Empagliflozin's core US composition-of-matter protection is generally reported to expire in the 2027-2028 window, with earliest generic entry estimates around February 2029, but a stack of secondary formulation and method-of-use patents could push meaningful generic penetration later, and settlement agreements make the effective date uncertain [16]. Payer coverage for a branded vicadrostat/empagliflozin combination will demand meaningful outcome differentiation, not incremental biomarker wins.

Worth watching, on a slow clock. This is a serious program from a serious company with a mechanism that has been de-risked at the pathway level by finerenone. The specific signal to watch is the interim analysis or futility check on EASi-KIDNEY, plausibly around 2027 but not publicly confirmed by Boehringer, which will be the first look at whether the combination beats empagliflozin monotherapy on a composite endpoint. A clean win there would validate the entire Phase 3 program and reprice Boehringer's post-2028 cardio-renal franchise. A miss would kill the T2D and HF indications by implication. The competitive read is equally important: baxdrostat's PDUFA in Q2 2026 for hypertension and its dapagliflozin-combination CKD outcomes trial completing in early 2028 mean AstraZeneca could get to market with an ASI first and read out a directly analogous CKD outcomes study on a similar timeline [13][14]. Vicadrostat's edge has to come from selectivity, safety, or larger effect size in the combination, not from being first. The commercial context is that Boehringer is trying to build the next Jardiance before Jardiance faces generic pressure, and vicadrostat plus empagliflozin fixed-dose combination is the plausible successor product. Check back on: (1) Phase 3 CKD interim if disclosed, (2) baxdrostat's CKD outcomes trial readout timing versus EASi-KIDNEY, (3) any updated Phase 2 heart failure data from smaller mechanistic studies, (4) hyperkalemia and adverse event rates in the meta-analysis publications now appearing in JACC Advances and J Hypertens [11][12]. This is not a near-term catalyst stock story, it is a 2028-2030 platform expansion for a private pharma.